Nano-x Imaging (NNOX) Shares Plunge 20.31% as Profitability Concerns Overshadow FDA Clearance, French Expansion

The share price of Nano-x Imaging (NNOX) fell to a record low this month, with an intraday decline of 9.56% on Feb. 4. The stock has now declined 20.31% over five consecutive trading days, marking its worst performance since the company’s public listing. The recent sell-off follows mixed market reactions to regulatory and strategic developments, despite a pivotal FDA clearance for its TAP2D technology.

On Feb. 3, the U.S. Food and Drug Administration granted 510(k) clearance for Nano-x’s TAP2D cloud-enabled image enhancement feature, a key milestone allowing its Nanox.ARC and Nanox.ARC X systems to function as primary diagnostic tools in the U.S. The technology generates 2D images from tomosynthesis scans without additional radiation, streamlining workflows and enhancing diagnostic efficiency. CEO Erez Meltzer highlighted the clearance as a step toward removing the “adjunctive use” label in the U.S., potentially boosting adoption in cost-sensitive healthcare facilities. Separately, the company secured a partnership with Althea France to distribute its systems in the French market, expanding its European footprint where the devices are already CE-certified as primary diagnostic tools.

Despite these advances, the stock’s sharp decline reflects investor skepticism about scaling profitability. While Nano-x reported $12.3 million in revenue with 15.19% year-over-year growth, its $188.25 million market cap remains under pressure, trading below estimated fair value. A recent $15 million stock offering to fund operations has also raised concerns about equity dilution. Analysts note the company’s 4.14 current ratio indicates liquidity stability, but its small market cap and recent volatility—a 15% drop over seven days—suggest limited confidence in near-term profitability. The TAP2D rollout and French expansion could drive long-term value, but investors may require clearer evidence of revenue diversification and operational efficiency to reverse the downward trend.